Last updated on May 2020

Derazantinib in Subjects With FGFR2 Gene Fusion- Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma


Brief description of study

This pivotal, open-label, single-arm study will evaluate the anti-cancer activity of derazantinib by Objective Response Rate (ORR) by central radiology review as per RECIST v1.1 in subjects with inoperable or advanced intrahepatic cholangiocarcinoma (iCCA) whose tumors harbor FGFR2 gene fusions (by FISH performed by the central laboratory) or FGFR2 gene mutations or amplifications (based on NGS testing performed or commissioned by the respective study center) and who received at least one prior regimen of systemic therapy. Subjects will be dosed orally once per day at 300 mg of derazantinib capsules.

Clinical Study Identifier: NCT03230318

Find a site near you

Start Over

St. James's Hospital

Dublin, Ireland
4.86miles
  Connect »